ArticleObesity pillars2025
Short-term pre-meal whey protein microgel supplementation reduces postprandial glycemia and appetite in adults with overweight: An open-label randomised controlled trial.
Article in Obesity pillars, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06593769 (Glycemic and Appetite Effects of a Pre-meal Whey-Protein Microgel), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glycemic and Appetite Effects of a Pre-meal Whey-Protein Microgel (the GAP Study)
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Premeal whey protein (WP) consumption may reduce postprandial glucose (PPG) levels and appetite. We assessed the effects of twice daily consumption of a low-dose non-gelling novel WP formulation (WP microgel [WPM]) on PPG, self-reported appetite, and ad-libitum food consumption. Methods: This was a randomized, prospective, open-label, controlled, single-center crossover study, and adults with BMI 27-35 kg/m Result: 18 individuals (8 females, median age 57 years, BMI 29.8 kg/m Conclusions: A 125 mL pre-meal dose of WPM consumed twice daily before breakfast and lunch for 4 days in adults with obesity significantly reduced breakfast PPG and had a moderate appetite-suppressing effect, which led to a significantly lower energy consumption during ad-libitum lunch (NCT06593769).
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.